Positive results from a mid-stage study apparently weren’t enough to raise investor confidence in Praxis Precision Medicines ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place ...

The White House set a 60-day deadline for drugmakers to agree on “most favored nation” prices for Medicaid as well as for ...

Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

The 17 advisers fired last month by Robert F. Kennedy Jr. urged alternatives to ACIP be organized to limit further ...

Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results CEO Yvonne Greenstreet ...

Discover the latest breakthroughs in Alzheimer's research, diagnosis, and prevention in this expert-led podcast series.

Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office ...